Literature DB >> 21255855

High-throughput process development for biopharmaceutical drug substances.

Rahul Bhambure1, Kaushal Kumar, Anurag S Rathore.   

Abstract

Quality by Design (QbD) is gaining industry acceptance as an approach towards development and commercialization of biotechnology therapeutic products that are expressed via microbial or mammalian cell lines. In QbD, the process is designed and controlled to deliver specified quality attributes consistently. To acquire the enhanced understanding that is necessary to achieve the above, however, requires more extensive experimentation to establish the design space for the process and the product. With biotechnology companies operating under ever-increasing pressure towards lowering the cost of manufacturing, the use of high-throughput tools has emerged as a necessary enabler of QbD in a time- and resource-constrained environment. We review this topic for those in academia and industry that are engaged in drug substance process development.
Copyright © 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21255855     DOI: 10.1016/j.tibtech.2010.12.001

Source DB:  PubMed          Journal:  Trends Biotechnol        ISSN: 0167-7799            Impact factor:   19.536


  12 in total

1.  Analytical characterization of a monoclonal antibody therapeutic reveals a three-light chain species that is efficiently removed using hydrophobic interaction chromatography.

Authors:  Rachel B Wollacott; Paul L Casaz; Trevor J Morin; H Lily Zhu; Roger S Anderson; Gregory J Babcock; John Que; William D Thomas; Sadettin S Ozturk
Journal:  MAbs       Date:  2013-08-19       Impact factor: 5.857

Review 2.  The therapeutic monoclonal antibody market.

Authors:  Dawn M Ecker; Susan Dana Jones; Howard L Levine
Journal:  MAbs       Date:  2015       Impact factor: 5.857

Review 3.  Improving monoclonal antibody selection and engineering using measurements of colloidal protein interactions.

Authors:  Steven B Geng; Jason K Cheung; Chakravarthy Narasimhan; Mohammed Shameem; Peter M Tessier
Journal:  J Pharm Sci       Date:  2014-09-10       Impact factor: 3.534

Review 4.  Adaptation of high-throughput screening in drug discovery-toxicological screening tests.

Authors:  Paweł Szymański; Magdalena Markowicz; Elżbieta Mikiciuk-Olasik
Journal:  Int J Mol Sci       Date:  2011-12-29       Impact factor: 5.923

Review 5.  Fabrication approaches for high-throughput and biomimetic disease modeling.

Authors:  Mackenzie L Grubb; Steven R Caliari
Journal:  Acta Biomater       Date:  2021-03-11       Impact factor: 10.633

6.  Optically induced thermal gradients for protein characterization in nanolitre-scale samples in microfluidic devices.

Authors:  D M Sagar; Samir Aoudjane; Matthieu Gaudet; Gabriel Aeppli; Paul A Dalby
Journal:  Sci Rep       Date:  2013       Impact factor: 4.379

7.  Development and scale-up of a commercial fed batch refolding process for an anti-CD22 two chain immunotoxin.

Authors:  Thomas Linke; Matthew T Aspelund; Christopher Thompson; Guoling Xi; Andrew Fulton; Michaela Wendeler; Timothy M Pabst; Xiangyang Wang; William K Wang; Kripa Ram; Alan K Hunter
Journal:  Biotechnol Prog       Date:  2014-09-02

8.  High throughput automated microbial bioreactor system used for clone selection and rapid scale-down process optimization.

Authors:  M Lourdes Velez-Suberbie; John P J Betts; Kelly L Walker; Colin Robinson; Barney Zoro; Eli Keshavarz-Moore
Journal:  Biotechnol Prog       Date:  2017-08-10

Review 9.  Microfluidic devices: useful tools for bioprocess intensification.

Authors:  Marco P C Marques; Pedro Fernandes
Journal:  Molecules       Date:  2011-09-30       Impact factor: 4.411

Review 10.  Sophisticated Cloning, Fermentation, and Purification Technologies for an Enhanced Therapeutic Protein Production: A Review.

Authors:  Sanjeev K Gupta; Pratyoosh Shukla
Journal:  Front Pharmacol       Date:  2017-07-04       Impact factor: 5.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.